Business Description
TC BioPharm (Holdings) PLC
ISIN : US87807D4007
Share Class Description:
FRA:T0U: ADRDescription
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.61 | |||||
| Equity-to-Asset | 0.29 | |||||
| Debt-to-Equity | 0.83 | |||||
| Debt-to-EBITDA | -0.32 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EPS without NRI Growth Rate | 40.4 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 70.94 | |||||
| 9-Day RSI | 61.57 | |||||
| 14-Day RSI | 57.36 | |||||
| 12-1 Month Momentum % | -24.31 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.12 | |||||
| Quick Ratio | 1.12 | |||||
| Cash Ratio | 0.28 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | 1.35 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -274.3 | |||||
| ROA % | -68.16 | |||||
| ROIC % | -136.89 | |||||
| 3-Year ROIIC % | 198.13 | |||||
| ROC (Joel Greenblatt) % | -219.43 | |||||
| ROCE % | -161.28 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.73 | |||||
| Price-to-Tangible-Book | 2.47 | |||||
| EV-to-EBIT | -10.55 | |||||
| EV-to-EBITDA | -11.05 | |||||
| EV-to-Forward-Revenue | 0.01 | |||||
| EV-to-FCF | -11.18 | |||||
| Earnings Yield (Greenblatt) % | -9.48 | |||||
| FCF Yield % | -9.04 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
TC BioPharm (Holdings) PLC Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -487.456 | ||
| Beta | 1.84 | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 109.46 | ||
| 14-Day RSI | 57.36 | ||
| 14-Day ATR (€) | 5.959189 | ||
| 20-Day SMA (€) | 106.92 | ||
| 12-1 Month Momentum % | -24.31 | ||
| 52-Week Range (€) | 6.6 - 400 | ||
| Shares Outstanding (Mil) | 0.51 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
TC BioPharm (Holdings) PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
TC BioPharm (Holdings) PLC Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
TC BioPharm (Holdings) PLC Frequently Asked Questions
What is TC BioPharm (Holdings) PLC(FRA:T0U)'s stock price today?
The current price of FRA:T0U is €132.00. The 52 week high of FRA:T0U is €400.00 and 52 week low is €6.60.
When is next earnings date of TC BioPharm (Holdings) PLC(FRA:T0U)?
The next earnings date of TC BioPharm (Holdings) PLC(FRA:T0U) is .
Does TC BioPharm (Holdings) PLC(FRA:T0U) pay dividends? If so, how much?
TC BioPharm (Holdings) PLC(FRA:T0U) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers